Patients who are considered candidates for surgical treatment at the time of study entry
Patients who have received pituitary irradiation within the last ten years prior to visit 1
Patients who have had any previous pasireotide treatment
Patients who have been treated with mitotane during the last 6 months prior to Visit 1
Diabetic patients on antihyperglycemic medications with poor glycemic control as evidenced by HbA1c \>8%
Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF \>470 ms, hypokalemia, uncontrolled hypothyroidism, family history of long QT syndrome, or concomitant medications known to prolong QT interval
Female patients who are pregnant or lactating, or are of childbearing potential (defined as all women physiologically capable of becoming pregnant) and not practicing an effective method of contraception/birth control. Sexually active males must use a condom during intercourse while taking the drug and for 2 months after the last dose of study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
Clareo Health | Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
